TABLE 2.

Univariate analysis for survival in all single node patients

Five‐year (%)	OS	P value	LRFS	P value	RRFS	P value	DMFS	P value
Age (y)
<65	69.1	.315	64.0	.796	64.9	.386	68.7	.245
≥65	59.6		59.6		61.3		57.4
Gender
Male	68.5	.498	63.8	.580	64.5	.575	67.8	.573
Female	66.1		63.9		64.2		66.4
Primary site
Buccal	69.6	.329	63.2	.277	65.5	.390	68.8	.344
Tongue	61.6		56.9		57.1		60.9
Mouth floor	100		100		90.0		100
Retromolar trigone	80.0		80.0		80.0		80.0
Gingiva	70.8		70.8		70.8		70.8
Lip	50.0		50.0		60.0		50.0
Hard palate	66.7		66.7		66.7		66.7
Differentiation
Well/moderate	71.2	.001	66.3	.019	67.0	.021	70.5	.003
Poor	40.9		40.9		40.9		41.3
pT
T1/2	74.2	.009	66.8	.095	68.3	.081	74.3	.005
T3/4	63.8		61.4		61.7		62.7
LVI
Positive	68.5	.741	53.8	.109	53.6	.118	68.5	.816
Negative	68.1		64.8		65.6		67.4
PNI
Positive	60.7	.019	56.3	.021	56.7	.019	59.4	.009
Negative	74.6		70.2		71.2		74.6
Margin
Clear	69.5	.293	65.5	.231	65.8	.323	68.9	.271
Close	66.4		61.4		62.7		65.9
Adjuvant therapy
No	72.1	.253	65.9	.671	64.7	.869	72.1	.175
Yes	66.3		62.8		64.3		65.4
Adjuvant therapy
No	72.1	.270	65.9	.525	64.7	.600	72.1	.213
RT	73.0		69.1		70.4		71.7
CCRT	60.5		57.2		58.9		59.8

Abbreviations: CCRT, concurrent chemoradiaiton; DMFS, distant metastasis‐free survival; LRFS, local recurrence‐free survival; LVI, lymphovascular invasion; OS, overall survival; PNI, perineural invasion; RRFS, regional recurrence‐free survival; RT, radiation therapy.